Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Q1 2026 revenue reached $19.80B, up 55.5% year over year, driven by Mounjaro revenue of $8.66B (+125%) and Zepbound revenue of $4.16B (+80%). Despite strong growth, realized prices fell 13% in Q1 due to Mounjaro’s inclusion on China’s national reimbursement list and lower U.S. cash-pay rates. The stock also faces competitive pressure, with Wegovy outselling Zepbound by about 1.5x at a comparable launch stage. Additional caution comes from the Supreme Court rejecting Lilly’s Medicaid fraud appeal. Analysts show a consensus target of $1,210 and a base-case model of $1,485.05 by May 2030, with a bull case of $1,598.24 and a bear case of $1,070.70. Reaching $1,800 would require a 76.2% gain and substantial additional multiple expansion on forward EPS.

"Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). Yet shares trade at $1,021.41, down on the year. What's Holding Lilly Back Right Now Lilly is down 4.63% year to date even after a 10.37% one-month bounce and a 3.36% one-week move. Two pressures on the multiple: First, pricing. Realized prices fell 13% in Q1 as Mounjaro hit China's national reimbursement list and U.S. cash-pay rates came down."

"Second, competitive read. Novo Nordisk's Wegovy pill is still outselling Lilly's Zepbound at a comparable launch stage by roughly 1.5x. Add the Supreme Court rejecting Lilly's Medicaid fraud appeal, and buyers stay cautious. Beta of 0.481 means this stock moves on earnings. Wall Street Sees 18% Upside. Our Model Sees More Analysts are constructive. The Street has 6 Strong Buy, 18 Buy, 6 Hold, and 1 Sell ratings, with a consensus target of $1,210. That implies roughly 18% upside."

"Our base-case model lands at $1,485.05 by May 2030, with a bull case of $1,598.24 and bear case of $1,070.70. Confidence is 90%. Analysts are anchoring on near-term pricing noise and underweighting the orforglipron ramp. 77% of analysts are already bullish, and trailing earnings growth of 169.9% YoY is doing the heavy lifting that consensus has not fully priced."

"Reaching $1,800 from today's price of $1,021.41 requires a 76.2% gain. With forward EPS of $35.47, a price of $1,800 implies a forward P/E of 51. Our base case of $1,165.39 already implies 35x, meaning the bold target needs roughly 16 turns of additional multiple expansion on today's EPS base. EPS is moving fast. 2026 guidance is $35.5 to $37, up from a prior $"

Read at 24/7 Wall St.